UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 11, 2021
NASCENT BIOTECH, INC. |
(Exact name of registrant as specified in its charter) |
Nevada |
| 000-55299 |
| 46-5001940 |
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
623 17th Street Suite 4 Vero Beach FL . |
| 32970 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code (612) 961-5656
N/A |
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 OTHER EVENTS
On August 11, 2021, the Company issued a convertible for $200,000 with an annual interest rate of 10%. The Company may elect to pay the note back at any time prior to February 11, 2022 after which the Holder may elect to convert any unpaid principal of the note and accrued interest.
On August 16, 2021, the Company paid in full the Convertible note held by Black Ice Advisors LLC. The note including principal and interest of $140,000 that was convertible to common stock of the Company. By paying the note, no conversion occurred.
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NASCENT BIOTECH, INC. |
|
|
|
/s/ Sean Carrick |
|
Sean Carrick |
|
President |
|
|
|
Date: August 17, 2021 |
|
3 |
